Study aims to assess the diagnosis and management value of blood-based biomarkers and Neurophet AQUA for Alzheimer's disease
[by Ji, Yong Jun] Neurophet, an AI-based company specializing in the diagnosis and treatment of brain disorders, announced on November 25 that it is conducting a joint research collaboration with the Florey Institute of Neuroscience and Mental Health (hereinafter referred to as Florey) in Australia on its brain neurodegeneration imaging analysis software, Neurophet AQUA.
The joint research initiative will focus on advancing dementia diagnosis in Australian Memory Clinics and will assess the clinical utility of blood-based biomarkers and Neurophet AQUA in the diagnosis and management of Alzheimer's disease in real-world settings. Through the use of Neurophet AQUA, the two companies plan to accelerate their collaborative efforts under the theme of ‘Enhanced Dementia Diagnosis.’
Based in Melbourne, Australia, Florey employs more than 500 researchers and support personnel and is recognized as the largest and most influential brain research institute in the Southern Hemisphere. Florey's research portfolio centers on depression, schizophrenia, bipolar disorder, and neurodegenerative diseases associated with cognitive impairment.
Peter van Wijngaarden, Director of Florey and an emeritus professor of ophthalmology at the University of Melbourne, is focusing on research into biomarkers for neurodegenerative diseases. "Through this collaboration with Neurophet, we aim to accelerate our research on advanced dementia diagnosis," he stated.
"Through this joint research collaboration, we intend to leverage our AI-based brain imaging analysis solution to advance global dementia diagnosis. We will make every effort to demonstrate the clinical usefulness of biomarkers for the early diagnosis of Alzheimer's disease," said Jake Junkil Been, co-CEO of Neurophet.